<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Genes &amp; Cells</journal-id><journal-title-group><journal-title xml:lang="en">Genes &amp; Cells</journal-title><trans-title-group xml:lang="ru"><trans-title>Гены и Клетки</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Genes and Cells</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-1829</issn><issn publication-format="electronic">2500-2562</issn><publisher><publisher-name xml:lang="en">Human Stem Cells Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">122005</article-id><article-id pub-id-type="doi">10.23868/202104013</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The hipotises of the immune system's role in carcinogenesis</article-title><trans-title-group xml:lang="ru"><trans-title>Гипотеза о роли иммунной системы в канцерогенезе</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Slepov</surname><given-names>Y. K</given-names></name><name xml:lang="ru"><surname>Слепов</surname><given-names>Ю. К</given-names></name></name-alternatives><email>slepovurij95@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Laushkin</surname><given-names>M. A</given-names></name><name xml:lang="ru"><surname>Лаушкин</surname><given-names>М. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Deev</surname><given-names>R. V</given-names></name><name xml:lang="ru"><surname>Деев</surname><given-names>Р. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">I.I. MechnikovNorth-Western State Medical University</institution></aff><aff><institution xml:lang="ru">Северо-Западный Государственный Университет им. И.И. Мечникова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-03-15" publication-format="electronic"><day>15</day><month>03</month><year>2021</year></pub-date><volume>16</volume><issue>1</issue><issue-title xml:lang="en">VOL 16, NO1 (2021)</issue-title><issue-title xml:lang="ru">ТОМ 16, №1 (2021)</issue-title><fpage>82</fpage><lpage>91</lpage><history><date date-type="received" iso-8601-date="2023-01-16"><day>16</day><month>01</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, Эко-Вектор</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2024-03-15"/></permissions><self-uri xlink:href="https://genescells.ru/2313-1829/article/view/122005">https://genescells.ru/2313-1829/article/view/122005</self-uri><abstract xml:lang="en"><p>The presented controversial hypothesis is an attempt to reflect on the role of the adaptive immune response in carcinogenesis. It is a well-known fact that the most of the signaling pathways which are participating in embryogenesis and regeneration are also active in tumor growth. Considering their presence in different evolutionary groups, there's such a contradiction that with same mechanisms of proliferation, animals with high regenerative potential are less predisposed to malignancy than mammals. Comparing these two groups, it's being discovered that despite the importance of immune control as a factor impeding carcinogenesis, the animals' immune system with high regenerative potential is less developed. The above is a reading of the complete or partial absence of the adaptive link of immunity. These described distinctions have formed the basis of the hypothesis of the procarcino-genic role of the adaptive immune response.</p></abstract><trans-abstract xml:lang="ru"><p>Представленная дискуссионная гипотеза является попыткой размышления о роли адаптивного иммунного ответа в канцерогенезе. Известен факт того, что большинство сигнальных путей, участвующих в эмбриогенезе и регенерации, также активны и при опухолевом росте. Учитывая их наличие у представителей разных эволюционных групп животных, возникает противоречие, заключающееся в том, что при одинаковых механизмах пролиферации у животных с высоким регенеративным потенциалом предрасположенность к развитию злокачественных новообразований ниже, чем, например, у млекопитающих. Сравнивая эти группы, обнаруживается, что, несмотря на существующее мнение о важности иммунного контроля как фактора, препятствующего канцерогенезу, иммунная система у животных с высокими темпами регенерации менее развита; в частности, это заключается в полном или частичном отсутствии адаптивного звена иммунитета. Описанные различия легли в основу гипотезы о проканцерогенной роли адаптивного иммунного ответа.</p></trans-abstract><kwd-group xml:lang="en"><kwd>carcinogenesis</kwd><kwd>embryogenesis</kwd><kwd>regeneration</kwd><kwd>proliferation</kwd><kwd>differentiation</kwd><kwd>immune system</kwd><kwd>adaptive immune response</kwd><kwd>biological evolution</kwd><kwd>signaling pathways</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>канцерогенез</kwd><kwd>эмбриогенез</kwd><kwd>регенерация</kwd><kwd>пролиферация</kwd><kwd>дифференцировка</kwd><kwd>иммунная система</kwd><kwd>адаптивный иммунный ответ</kwd><kwd>биологическая эволюция</kwd><kwd>сигнальные пути</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Dvorak H.F. Tumors: wounds that do not heal-redux. Cancer Immunol. Res. 2015; 3(1): 1-11.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Peiris T.H., Hoyer K.K., Oviedo N.J. Innate immune system and tissue regeneration in planarians: an area ripe for exploration. Semin. Immunol. 2014; 26(4): 295-302.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Ratajczak M.Z., Bujko K., Mack A. et al. Cancer from the perspective of stem cells and misappropriated tissue regeneration mechanisms. Leukemia 2018; 32: 2519-26.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Nestor J. O., Wendy S.B. Regeneration: The origin of cancer or a possible cure. Semin. Cell Dev. Biol. 2009; 20(5): 557-64.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Matejuk A. Skin. Immunity. Arch. Immunol. Ther. Exp. 2018; 66(1): 45-54.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Tomar N., De R.K. A brief outline of the immune system. Methods Mol. Biol. 2014; 1184: 3-12.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Gombart A.F., Pierre A., Maggini S. A review of micronutrients and the immune system-working in harmony to reduce the risk of infection. Nutrients 2020; 12(1): 236-77.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Mamuka G.B., Baranov E. From cancer to rejuvenation: incomplete regeneration as the missing link (Part I: the same origin, different outcomes). Future Science OA. 2020; 6(3): FSO450.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Yu J.M., Sun W., Wang Z.H. et al. TRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcription. Nat. Commun. 2019; 10(1): 5720-36.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Гаршин В.Г. Воспалительные разрастания эпителия, их биологическое значение и отношение к проблеме рака. Москва, Ленинград: Издательство Медгиз; 1939.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Murtaugh L.C., Keefe M.D. Regeneration and repair of the exocrine pancreas. Ann. Rev. Physiol. 2015; 77: 229-49.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Bonventre J.V. Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J.Am. Soc. Nephrol. 2003; 14(1): 55-61.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Murugan A.K. mTOR: Role in cancer, metastasis and drug resistance. Semin Cancer Biol. 2019; 59: 92-111.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Mossmann D., Park S., Hall M.N. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat. Rev. Cancer 2018; 18(12): 744-57.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Taciak B., Pruszynska I., Kiraga L. et al. Wnt signaling pathway in development and cancer. J. Physiol. Pharmacol. 2018; 69(2): 185-96.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Groner B., von Manstein V. Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition. Mol. Cell Endocrinol. 2017; 451: 1-14.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Chen S., Li F., Xu D. et al. The function of RAS mutation in cancer and advances in its drug research. Curr. Pharm. Des. 2019; 25(10): 1105-14.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Riverso M., Montagnani V., Stecca B. KLF4 is regulated by RAS/ RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth. Oncogene 2017; 36(23): 3322-33.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Rizzino A., Wuebben E.L. Sox2/Oct4: A delicately balanced partnership in pluripotent stem cells and embryogenesis. Biochim. Biophys. Acta 2016; 1859(6): 780-91.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Novak D., Huser L., Elton J.J. et al. SOX2 in development and cancer biology. Semin. Cancer Biol. 2020; 67(1): 74-82.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Lee C.J., Sung P.L., Kuo M.H. et al. Crosstalk between SOX2 and cytokine signaling in endometrial carcinoma. Sci. Rep. 2018; 8(1): 17550-62.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Arnold K., Sarkar A., Yram M.A. et al. Sox2(+) adult stem and progenitor cells are important for tissue regeneration and survival of mice. Cell Stem Cell 2011; 9(4): 317-29.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Jiang W.L., Zhang P.F., Li G.F. et al. Oct-4 is associated with gastric cancer progression and prognosis. OncoTargets Ther. 2016; 9: 517-22.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Fatima N., Srivastava A.N., Nigam J. et al. Clinicopathological correlation of cancer stem cell markers Oct-4 and CD133 expression as prognostic factor in malignant lesions of gallbladder: An immunohistochemical study. Indian. J. Pathol. Microbiol. 2019; 62(3): 384-90.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Lu H., Zhang L.H., Yang L. et al. The PI3K/Akt/FOXO3a pathway regulates regeneration following spinal cord injury in adult rats through TNF-a and p27kip1 expression. Int. J. Mol. Med. 2018; 41(5): 2832-8.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Yang C., Liu X., Zhao K. miRNA-21 promotes osteogenesis via the PTEN/PI3K/Akt/HIF-1a pathway and enhances bone regeneration in critical size defects. Stem Cell Res. Ther. 2019; 10(1): 65.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Murakami M., Ichisaka T., Maeda M. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol. Cell. Biol. 2004; 24(15): 6710-8.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Marquard F.E., Jucker M. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. Biochem. Pharmacol. 2020; 172: 113729. doi: 10.1016/j.bcp.2019.113729.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Sharma V.R., Gupta G.K., Sharma A.K. PI3K/Akt/mTOR intracellular pathway and breast cancer: factors, mechanism and regulation. Curr. Pharm. Des. 2017; 23(11): 1633-8.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Ediriweera M.K., Tennekoon K.H., Samarakoon S.R. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin. Cancer Biol. 2019; 59: 147-60.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Zhan T., Rindtorff N., Boutros M. Wnt signaling in cancer. Oncogene 2017; 36(11): 1461-73.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Girardi F., Le Grand F. Wnt signaling in skeletal muscle development and regeneration. Prog. Mol. Biol. Transl. Sci. 2018; 153: 157-79.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Leucht P., Lee S., Yim N. Wnt signaling and bone regeneration: Can't have one without the other. Biomaterials 2019; 196: 46-50.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Zhou Y., Jin J., Feng M., Zhu D. Wnt signaling in inflammation in tissue repair and regeneration. Curr. Protein Pept. Sci. 2019; 20(8): 829-43.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Sackett S.D., Gao Y., Shin S. Foxl1 promotes liver repair following cholestatic injury in mice. Lab. Invest. 2009; 89(12): 1387-96.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Chen X., Deng M., Ma L. et al. Inhibitory effects of forkhead box L1 gene on osteosarcoma growth through the induction of cell cycle arrest and apoptosis. Oncol. Rep. 2015; 34(1): 265-71.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Zhang G., He P., Gaedcke J. et al. FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer. Cancer Res. 2013; 73(17): 5416-25.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Tresini M., Lorenzini A., Torres C. et al. Modulation of replicative senescence of diploid human cells by nuclear ERK signaling. J. Biol. Chem. 2007; 282(6): 4136-51.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Schmid C.A., Robinson M.D., Scheifinger N.A. et al. DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B. cell lymphoma. J. Exp. Med. 2015; 212(5): 775-92.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Hijiya N., Tsukamoto Y., Nakada C. et al. Genomic loss of DUSP4 contributes to the progression of intraepithelial neoplasm of pancreas to invasive carcinoma. Cancer Res. 2016; 76(9): 2612-25.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Zhu X., Liu R., Guan J. et al. Jak2a regulates erythroid and myeloid hematopoiesis during zebrafish embryogenesis. Int. J. Med. Sci. 2017; 14(8): 758-63.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Owen K.L., Brockwell N.K., Parker B.S. JAK-STAT signaling: A doubleedged sword of immune regulation and cancer progression. Cancers (Basel) 2019; 11(12): 2002-28.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Groner B., Hennighausen L. The versatile regulation of cellular events by Jak-Stat signaling: from transcriptional control to microtubule dynamics and energy metabolism. Horm. Mol. Biol. Clin. Investig. 2012; 10(1): 193-200.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Fey D., Matallanas D., Rauch J. et al. The complexities and versatility of the RAS-to-ERK signalling system in normal and cancer cells. Semin. Cell Dev. Biol. 2016; 58: 96-107.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Delire B., Starkel P. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. Eur. J. Clin. Invest. 2015; 45(6): 609-23.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Yue J., Xiong W., Ferrell J.E. B-Raf and C-Raf are required for Ras-stimulated p42 MAP kinase activation in Xenopus egg extracts. Oncogene 2006; 25(23): 3307-15.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Koera K., Nakamura K., Nakao K. et al. K-ras is essential for the development of the mouse embryo. Oncogene 1997; 15(10): 1151-9.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Borday C., Cabochette P., Parain K. et al. Antagonistic crossregulation between Wnt and Hedgehog signalling pathways controls post-embryonic retinal proliferation. Dev. 2012; 139(19): 3499-509.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Skoda A.M., Simovic D., Karin V. The role of the Hedgehog signaling pathway in cancer: A comprehensive review. Bosn. J. Basic Med. Sci. 2018; 18(1): 8-20.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Yoshida G.J. Emerging roles of Myc in stem cell biology and novel tumor therapies. J. Exp. Clin. Cancer Res. 2018; 37: 173. doi: 10.1186/ s13046-018-0835-y.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Christen B., Robles V., Raya M. et al. Regeneration and reprogramming compared. BMC Biol. 2010; 8: 5-19.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Gogna R., Shee K., Moreno E. Cell competition during growth and regeneration. Ann. Rev. Genet. 2015; 49: 697-718.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Aster J.C., Pear W.S., Blacklow S.C. The varied roles of notch in cancer. Ann. Rev. Pathol. 2017; 12: 245-75.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Saturnino A.P., Lust K., Wittbrodt J. Notch signalling patterns retinal composition by regulating atoh7 during post-embryonic growth. Dev. 2018; 145: dev169698. doi:10.1242/dev.169698.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Dobrokhotov O., Samsonov M., Sokabe M. et al. Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms. Clin. Trans. Med. 2018; 7(1): 23-37.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Noguchi S., Saito A., Nagase T. YAP/TAZ signaling as a molecular link between fibrosis and cancer. Int. J. Mol. Sci. 2018; 19(11): 3674-97.</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Meyn M.A. 3rd, Schreiner S.J., Dumitrescu T.P. et al. SRC family kinase activity is required for murine embryonic stem cell growth and differentiation. Mol. Pharmacol. 2005; 68(5): 1320-30.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Sirvent A., Mevizou R., Naim D. et al. Src family tyrosine kinases in intestinal homeostasis, regeneration and tumorigenesis. Cancers (Basel) 2020; 12(8): 2014. doi: 10.3390/cancers12082014.</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Hong A.W., Meng Z., Guan K.L. The Hippo pathway in intestinal regeneration and disease. Nat. Rev. Gastroenterol. Hepatol. 2016; 13(6): 324-37.</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Moya I.M., Halder G. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine. Nat. Rev. Mol. Cell Biol. 2019; 20(4): 211-26.</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Wu Z, Guan K.L. Hippo Signaling in Embryogenesis and Development. Trends Biochem. Sci. 2021; 46(1): 51-63.</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Bowling S., Di Gregorio A., Sancho M. et al. P53 and mTOR signalling determine fitness selection through cell competition during early mouse embryonic development. Nat. Commun. 2018; 9(1): 1763-75.</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Charni M., Aloni-Grinstein R., Molchadsky A. et al. p53 on the crossroad between regeneration and cancer. Cell Death Differ. 2017; 24(1): 8-14.</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Zhang J., Lee E.Y., Liu Y. pRB and E2F4 play distinct cell-intrinsic roles in fetal erythropoiesis. Cell Cycle 2010; 9(2): 371-6.</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Chang W.Y., Andrews J., Carter D.E. et al. Differentiation and injury-repair signals modulate the interaction of E2F and pRB proteins with novel target genes in keratinocytes. Cell Cycle 2006; 5(16): 1872-9.</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Luo Q., Wu X., Chang W. et al. ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness. Cell Death Differ. 2020; 27(6): 1981-97.</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Kent L.N., Leone G. The broken cycle: E2F dysfunction in cancer. Nat. Rev. Cancer 2019; 19(6): 326-38.</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006; 25(3): 409-16.</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Tao Y., Wang M., Chen E. et al. Liver Regeneration: Analysis of the main relevant signaling molecules. Mediators Inflamm. 2017; 2017: 4256352. doi:10.1155/2017/4256352.</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Toder V., Fein A., Carp H. et al. TNF-alpha in pregnancy loss and embryo maldevelopment: a mediator of detrimental stimuli or a protector of the fetoplacental unit? J. Assist. Reprod. Genet. 2003; 20(2): 73-81.</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Hata A., Chen Y.G. TGF-p Signaling from receptors to Smads. Cold Spring Harb. Perspect. Biol. 2016; 8(9): a022061. doi:10.1101/cshper-spect.a022061.</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Miyazono K., Katsuno Y., Koinuma D. et al. Intracellular and extracellular TGF-p signaling in cancer: some recent topics. Front. Med. 2018; 12(4): 387-411.</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Delaney K., Kasprzycka P., Ciemerych M.A. et al. The role of TGF-p1 during skeletal muscle regeneration. Cell Biol. Int. 2017; 41(7): 706-15.</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Wagner E.F., Nebreda A.R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 2009; 9(8): 537-49.</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Li Q.V., Dixon G., Verma N. et al. Genome-scale screens identify JNK-JUN signaling as a barrier for pluripotency exit and endoderm differentiation. Nat. Genet. 2019; 51(6): 999-1010.</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Majidinia M., Sadeghpour A., Yousefi B. The roles of signaling pathways in bone repair and regeneration. J. Cell Physiol. 2018; 233(4): 2937-48.</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Weinberg R.A. The biology of cancer. London: Taylor &amp; Francis Group Publishers; 2007.</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>Yazawa S., Umesono Y., Hayashi T. et al. Planarian Hedgehog/ Patched establishes anterior-posterior polarity by regulating Wnt signaling. PNAS USA 2009; 106(52): 22329-34.</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Currie K.W., Molinaro A.M., Pearson B.J. Neuronal sources of hedgehog modulate neurogenesis in the adult planarian brain. Elife 2016; 5: e19735. doi:10.7554/eLife.19735.</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>Peiris T.H., Ramirez D., Barghouth P.G. et al. The Akt signaling pathway is required for tissue maintenance and regeneration in planarians. BMC Dev. Biol. 2016; 16: 7.</mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation>Hosoda K., Morimoto M., Motoishi M. et al. Simple blood-feeding method for live imaging of gut tube remodeling in regenerating planarians. Dev. Growth Differ. 2016; 58(3): 260-9.</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation>Mehta A.S., Singh A. Insights into regeneration tool box: An animal model approach. Dev. Biol. 2019; 453(2): 111-29.</mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation>Lee Y., Nachtrab G., Klinsawat P.W. et al. Ras controls melanocyte expansion during zebrafish fin stripe regeneration. Dis. Models Mech. 2010; 3(7-8): 496-503</mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation>Singh B.N., Weaver C.V, Garry M.G. Hedgehog and wnt signaling pathways regulate tail regeneration. Stem Cells Dev. 2018; 27(20): 1426-37.</mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation>Nakatani Y., Nishidate M., Fujita M. et al. Migration of mesenchymal cell fated to blastema is necessary for fish fin regeneration. Dev. Growth Differ. 2008; 50(2): 71-83.</mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation>Hu J., Li J., Yue X. et al. Expression of the cancer stem cell markers ABCG2 and OCT-4 in right-sided colon cancer predicts recurrence and poor outcomes. Oncotarget. 2017; 8(17): 28463-70.</mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation>Yoshida G.J. Emerging roles of Myc in stem cell biology and novel tumor therapies J. Exp. Clin. Cancer Res. 2018; 37(1): 173-93.</mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation>Nguyen C., Yi C. YAP/TAZ signaling and resistance to cancer therapy. Trends Cancer 2019; 5(5): 283-96.</mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation>Hong B., van den Heuvel A.P., Prabhu V.V. et al. Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Curr. Drug Targets 2014; 15(1): 80-9.</mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation>Wang Q., Zou Y., Nowotschin S. et al. The p53 family coordinates wnt and nodal inputs in mesendodermal differentiation of embryonic stem cells. Cell Stem Cell 2017; 20(1): 70-86.</mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation>Hauton C., Smith V.J. Adaptive immunity in invertebrates: a straw house without a mechanistic foundation. Bioessays 2007; 29: 1138-46.</mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation>Chalmers I.W., Hoffmann K.F. Platyhelminth Venom Allergen-Like (VAL) proteins: revealing structural diversity, class-specific features and biological associations across the phylum. Parasitology 2012; 139: 1231-45.</mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation>Rodriguez R.M., Lopez-Vazquez A., Lopez-Larrea C. Immune systems evolution. Adv. Exp. MedBiol. 2012; 739: 237-51.</mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation>Pasupuleti M., Schmidtchen A., Malmsten M. Antimicrobial peptides: key components of the innate immune system. Crit. Rev. Biotechnol. 2012; 32: 143-71.</mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation>Altincicek B., Vilcinskas A. Comparative analysis of septic injury-inducible genes in phylogenetically distant model organisms of regeneration and stem cell research, the planarian Schmidtea mediterranea and the cnidarian Hydra vulgaris. Front. Zool. 2008; 5: 6-18.</mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation>Morita M., Best J.B. Electron microscopic studies of planarian regeneration. II. Changes in epidermis during regeneration. J. Exp. Zool. 1974; 187: 345-73.</mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation>Morita M. Phagocytic response of planarian reticular cells to heat-killed bacteria. Hydrobiologia 1991; 227: 193-9.</mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation>Morita M. Structure and function of the reticular cell in the planarian Dugesia dorotocephala. Hydrobiologia 1995; 305: 189-96.</mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation>Isolani M.E., Abril J.F., Salo E. et al. Planarians as a model to assess in vivo the role of matrix metalloproteinase genes during homeostasis and regeneration. PLoS One 2013; 8(2): e55649. doi:10.1371/journal. pone.0055649.</mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation>Rodgers A.K., Smith J.J., Voss S.R. Identification of immune and non-immune cells in regenerating axolotl limbs by single-cell sequencing. Exp. Cell. Res. 2020; 394(2): 112149. doi:10.1016/j.yexcr.2020.112149.</mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation>Godwin J.W., Pinto A.R., Rosenthal N.A. Macrophages are required for adult salamander limb regeneration. PNAS USA 2013; 110(23): 9415-20.</mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation>Bolanos-Castro L.A., Walters H.E., Garcia Vazquez R.O. et al. Immunity in salamander regeneration: Where are we standing and where are we headed? Dev. Dyn. 2020. doi: 10.1002/dvdy.251.</mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation>Leigh N.D., Dunlap G.S., Johnson K. et al. Transcriptomic landscape of the blastema niche in regenerating adult axolotl limbs at single-cell resolution. Nat. Commun. 2018; 9(1): 5153-67.</mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation>Lai S.L., Marin-Juez R., Stainier D.Y.R. Immune responses in cardiac repair and regeneration: a comparative point of view. Cell. Mol. Life Sci. 2019; 76(7): 1365-80.</mixed-citation></ref><ref id="B105"><label>105.</label><mixed-citation>Wang J. Neutrophils in tissue injury and repair. Cell Tissue Res. 2018; 371(3): 531-9.</mixed-citation></ref><ref id="B106"><label>106.</label><mixed-citation>Fahmy G.H., Sicard R.E. A role for effectors of cellular immunity in epimorphic regeneration of amphibian limbs. In Vivo 2002; 16(3): 179-84.</mixed-citation></ref><ref id="B107"><label>107.</label><mixed-citation>Hui S.P., Sheng D.Z., Sugimoto K., et al. Zebrafish regulatory T cells mediate organ-specific regenerative programs. Dev. Cell. 2017; 43(6): 659-72.</mixed-citation></ref><ref id="B108"><label>108.</label><mixed-citation>108.Fior J. Salamander regeneration as a model for developing novel regenerative and anticancer therapies. J. Cancer 2014; 5(8): 715-9.</mixed-citation></ref><ref id="B109"><label>109.</label><mixed-citation>Yatim K.M., Lakkis F.G. A brief journey through the immune system. Clin. J.Am. Soc. Nephrol. 2015; 10(7): 1274-81.</mixed-citation></ref><ref id="B110"><label>110.</label><mixed-citation>Kollmann T.R., Crabtree J., Rein-Weston A. et al. Neonatal innate TLR-mediated responses are distinct from those of adults. J. Immunol. 2009; 183: 7150-60.</mixed-citation></ref><ref id="B111"><label>111.</label><mixed-citation>Yerkovich S.T., Wikstrom M.E., Suriyaarachchi D. et al. Postnatal development of monocyte cytokine responses to bacterial lipopolysaccha-ride. Pediatr. Res. 2007; 62: 547-52.</mixed-citation></ref><ref id="B112"><label>112.</label><mixed-citation>Carr R. Neutrophil production and function in newborn infants. Br.J. Haematol. 2000; 110: 18-28.</mixed-citation></ref><ref id="B113"><label>113.</label><mixed-citation>De Wit D., Olislagers V., Goriely S. et al. Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns. Blood 2004; 103: 1030-2.</mixed-citation></ref><ref id="B114"><label>114.</label><mixed-citation>Walker J.C., Smolders M.A., Gemen E.F. et al. Development of lymphocyte subpopulations in preterm infants. Scand. J. Immunol. 2011; 73: 53-8.</mixed-citation></ref><ref id="B115"><label>115.</label><mixed-citation>Ygberg S., Nilsson A. The developing immune system - from foetus to toddler. Acta Paediatr. 2012; 101(2): 120-7.</mixed-citation></ref><ref id="B116"><label>116.</label><mixed-citation>Strunk T., Temming P., Gembruch U., et al. Differential maturation of the innate immune response in human fetuses. Pediatr. Res. 2004; 56: 219-26.</mixed-citation></ref><ref id="B117"><label>117.</label><mixed-citation>Sautois B., Fillet G., Beguin Y. Comparative cytokine production by in vitro stimulated mononucleated cells from cord blood and adult blood. Exp. Hematol. 1997; 25: 103-8.</mixed-citation></ref><ref id="B118"><label>118.</label><mixed-citation>Tolar J., Hippen K.L., Blazar B.R. Immune regulatory cells in umbilical cord blood: T regulatory cells and mesenchymal stromal cells. Br.J. Haematol. 2009; 147: 200-6.</mixed-citation></ref><ref id="B119"><label>119.</label><mixed-citation>Van den Berg J.P., Westerbreek E.A.M., van der Klis F.R.M. et al. Transplacental transport of IgG antibodies to preterm infants: a review of the literature. Early Hum. Dev. 2011; 87: 67-72.</mixed-citation></ref><ref id="B120"><label>120.</label><mixed-citation>Morbach H., Eichhorn E.M., Liese J.G. et al. Reference values for B cell subpopulations from infancy to adulthood. Clin. Exp. Immunol. 2010; 162(2): 271-9.</mixed-citation></ref><ref id="B121"><label>121.</label><mixed-citation>Lesina M., Kurkowski M.U., Ludes K. et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011; 19: 456-69.</mixed-citation></ref><ref id="B122"><label>122.</label><mixed-citation>Bellone G., Smirne C., Mauri F.A. et al. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol., Immunother. 2006; 55: 684-98.</mixed-citation></ref><ref id="B123"><label>123.</label><mixed-citation>Korkaya H., Kim G.I., Davis A. et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol. Cell 2012; 47: 570-84.</mixed-citation></ref><ref id="B124"><label>124.</label><mixed-citation>Fujisawa T., Joshi B.H., Puri R.K. IL-13 regulates cancer invasion and metastasis through IL-13Ralpha2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int. J. Cancer 2012; 131: 344-56.</mixed-citation></ref><ref id="B125"><label>125.</label><mixed-citation>Kioi M., Kawakami M., Shimamura T. et al. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer 2006; 107: 1407-18.</mixed-citation></ref><ref id="B126"><label>126.</label><mixed-citation>Kawakami M., Kawakami K., Kasperbauer J.L. et al. Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin. Cancer Res. 2003; 9: 6381-8.</mixed-citation></ref><ref id="B127"><label>127.</label><mixed-citation>Lasek W., Mackiewicz A., Czajka A. et al. Antitumor effects of the combination therapy with TNF-alpha gene-modified tumor cells and interleukin 12 in a melanoma model in mice. Cancer Gene Ther. 2000; 7(12): 1581-90.</mixed-citation></ref><ref id="B128"><label>128.</label><mixed-citation>Waterston A.M., Salway F., Andreakos E. et al. TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model. Br.J. Cancer 2004; 90(6): 1279-84.</mixed-citation></ref><ref id="B129"><label>129.</label><mixed-citation>Lee J. 3,3'-Diindolylmethane Inhibits TNF-a- and TGF-p-induced epithelial-mesenchymal transition in breast cancer cells. Nutr. Cancer 2019; 71(6): 992-1006.</mixed-citation></ref><ref id="B130"><label>130.</label><mixed-citation>Raaschou P., Frisell T., Askling J. et al. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann. Rheum. Dis. 2015; 74(12): 2137-43.</mixed-citation></ref><ref id="B131"><label>131.</label><mixed-citation>Shelton E., Laharie D., Scott F.I. et al. Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis. Gastroenterol. 2016; 151(1): 97-109.</mixed-citation></ref><ref id="B132"><label>132.</label><mixed-citation>Shi Q., Shen L., Gan J. et al. Integrative analysis identifies DNMTs against immune-infiltrating neutrophils and dendritic cells in colorectal cancer. Epigen. 2019; 14(4): 392-404.</mixed-citation></ref><ref id="B133"><label>133.</label><mixed-citation>Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141(1): 39-51.</mixed-citation></ref><ref id="B134"><label>134.</label><mixed-citation>Prizment A.E., Vierkant R.A., Smyrk T.C. et al. Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Women's Health Study. Mod. Pathol. 2016; 29(5): 516-27.</mixed-citation></ref><ref id="B135"><label>135.</label><mixed-citation>Xie F., Liu L.B., Shang W.Q. et al. The infiltration and functional regulation of eosinophils induced by TSLP promote the proliferation of cervical cancer cell. Cancer Lett. 2015; 364(2): 106-17.</mixed-citation></ref><ref id="B136"><label>136.</label><mixed-citation>Yin J.J., Selander K., Chirgwin J.M. et al. TGF-p signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 1999; 103(2): 197-206.</mixed-citation></ref><ref id="B137"><label>137.</label><mixed-citation>Becker C., Fantini M.C., Schramm C. et al. TGF-p suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004; 21(4): 491-501.</mixed-citation></ref><ref id="B138"><label>138.</label><mixed-citation>Hodgins J.J., Khan S.T., Park M.M. Killers 2.0: NK cell therapies at the forefront of cancer control. J. Clin. Invest. 2019; 129(9): 3499-510.</mixed-citation></ref><ref id="B139"><label>139.</label><mixed-citation>Terren I., Orrantia A., Vitalle J. et al. NK cell metabolism and tumor microenvironment. Front. Immunol. 2019; 10: 2277-8.</mixed-citation></ref><ref id="B140"><label>140.</label><mixed-citation>Fang F., Xiao W., Tian Z. NK cell-based immunotherapy for cancer. Semin. Immunol. 2017; 31: 37-54.</mixed-citation></ref><ref id="B141"><label>141.</label><mixed-citation>Pockley A.G., Vaupel P., Multhoff G. NK cell-based therapeutics for lung cancer. Expert Opin. Biol. Ther. 2020; 20(1): 23-33.</mixed-citation></ref><ref id="B142"><label>142.</label><mixed-citation>Bi J., Tian Z. NK cell dysfunction and checkpoint immunotherapy. Front. Immunol. 2019; 10: 1999-2009.</mixed-citation></ref><ref id="B143"><label>143.</label><mixed-citation>Sun J.C., Lanier L.L. Is there Natural Killer cell memory and can it be harnessed by vaccination? NK cell memory and immunization strategies against infectious diseases and cancer. Cold Spring Harb. Perspect. Biol. 2018; 10(10): a029538. doi:10.1101/cshperspect.a029538.</mixed-citation></ref><ref id="B144"><label>144.</label><mixed-citation>Wang Y., Liu J., Burrows P.D. et al. B Cell development and maturation. Adv. Exp. Med. Biol. 2020; 1254: 1-22.</mixed-citation></ref><ref id="B145"><label>145.</label><mixed-citation>Mizukami M., Hanagiri T., Yasuda M. et al. Antitumor effect of antibody against a SEREX-defined antigen (UOEH-LC-1) on lung cancer xenotransplanted into severe combined immunodeficiency mice. Cancer Res. 2007; 67(17): 8351-7.</mixed-citation></ref><ref id="B146"><label>146.</label><mixed-citation>Tokunaga R., Naseem M., Lo J.H. et al. B cell and B cell-related pathways for novel cancer treatments. Cancer Treat. Rev. 2019; 73: 10-9.</mixed-citation></ref><ref id="B147"><label>147.</label><mixed-citation>Pan M.R., Hou M.F., Chang H.C. et al. Cyclooxygenase-2 up-regu-lates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. J. Biol. Chem. 2008; 283(17): 11155-63.</mixed-citation></ref><ref id="B148"><label>148.</label><mixed-citation>Garg R., Blando J.M., Perez C.J. et al. Protein kinase C epsilon cooperates with PTEN loss for prostate tumorigenesis through the CXCL13-CXCR5 pathway. Cell Rep. 2017; 19(2): 375-88.</mixed-citation></ref><ref id="B149"><label>149.</label><mixed-citation>149.Wang, J.-Y. Editors. B cells in immunity and tolerance. Singapore: Springer Singapore; 2020.</mixed-citation></ref><ref id="B150"><label>150.</label><mixed-citation>Zhang Y., Gallastegui N., Rosenblatt J.D. Regulatory B cells in anti-tumor immunity. Int. Immunol. 2015; 27(10): 521-30.</mixed-citation></ref><ref id="B151"><label>151.</label><mixed-citation>O'Reilly C., Doroudian M., Mawhinney L. et al. Targeting MIF in cancer: therapeutic strategies, current developments, and future opportunities. Med. Res. Rev. 2016; 36(3): 440-60.</mixed-citation></ref><ref id="B152"><label>152.</label><mixed-citation>Суслов, А.П., Коноплева М.В., Третьяков О.Ю. Фундаментальная иммунобиология провоспалительных цитокинов и MIF. Медицинская иммунология. 2006; 8(1): 5-22. [Suslov A.P., Konopleva M.V., Tretiakov O.Yu. Fundamental immunobiology of pro-inflammatory cytokines and MIF. Med. Immunol. (Russia) 2006; 8(1): 5-22].</mixed-citation></ref><ref id="B153"><label>153.</label><mixed-citation>Schurigt U., Pfirschke C., Irmler I.M. et al. Interactions of T-helper cells with fibroblast-like synoviocytes: up-regulation of matrix metalloprotein-ases by macrophage migration inhibitory factor from both Th1 and Th2 cells. Arthritis Rheum. 2008; 58(10): 3030-40.</mixed-citation></ref><ref id="B154"><label>154.</label><mixed-citation>Penticuff J.C., Woolbright B.L., Sielecki T.M. et al. MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential. Nat. Rev. Urol. 2019; 16(5): 318-28.</mixed-citation></ref><ref id="B155"><label>155.</label><mixed-citation>Candido J., Hagemann T. Cancer-Related Inflammation. Journal of Clinical Immunology 2012; 33(1): 79-84.</mixed-citation></ref><ref id="B156"><label>156.</label><mixed-citation>Bui J.D., Schreiber R.D. Cancer immunosurveillance, immunoedit-ing and inflammation: independent or interdependent processes? Curr. Opin. Immunol. 2007; 19(2): 203-8.</mixed-citation></ref><ref id="B157"><label>157.</label><mixed-citation>Braumuller H., Wieder T., Brenner E. et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013; 494(7437): 361-5.</mixed-citation></ref><ref id="B158"><label>158.</label><mixed-citation>Valle-Mendiola A., Gutierrez-Hoya A., Lagunas-Cruz M. del C. et al. Pleiotropic effects of IL-2 on cancer: its role in cervical cancer. Mediators Inflamm. 2016; 2016: 2849523. doi:10.1155/2016/2849523.</mixed-citation></ref><ref id="B159"><label>159.</label><mixed-citation>Nalbant A. IL-17, IL-21, and IL-22 cytokines of T helper 17 cells in cancer. J. Interferon Cytokine Res. 2019; 39(1): 56-60.</mixed-citation></ref><ref id="B160"><label>160.</label><mixed-citation>Guery L., Hugues S. Th17 Cell plasticity and functions in cancer Immunity. Biomed Res. Int. 2015; 2015: 314620. doi:10.1155/2015/314620.</mixed-citation></ref><ref id="B161"><label>161.</label><mixed-citation>Hurtado C.G., Wan F., Housseau F. et al. Roles for Interleukin 17 and Adaptive Immunity in Pathogenesis of Colorectal Cancer. Gastroenterology 2018; 155(6): 1706-15.</mixed-citation></ref><ref id="B162"><label>162.</label><mixed-citation>Chen X., Wan J., Liu J. et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 2010; 69: 348-54.</mixed-citation></ref><ref id="B163"><label>163.</label><mixed-citation>Yamada Y., Saito H., Ikeguchi M. Prevalence and clinical relevance of Th17 cells in patients with gastric cancer. J. Surg. Res. 2012; 178: 685-91.</mixed-citation></ref><ref id="B164"><label>164.</label><mixed-citation>Punt S., Langenhoff J.M., Putter H. et al. The correlations between IL-17 vs Th17 cells and cancer patient survival: a systematic review. Oncoim-munol.2015; 4: 547-57.</mixed-citation></ref><ref id="B165"><label>165.</label><mixed-citation>Slingluff C.L., Cox A.L., Stover J.M. et al. Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68. Cancer Res. 1994; 54: 2731-7.</mixed-citation></ref><ref id="B166"><label>166.</label><mixed-citation>Boon T., Coulie P.G., Van den Eynde B. Tumor antigens recognized by T cells. Immunol. Today 1997; 18: 267-8.</mixed-citation></ref><ref id="B167"><label>167.</label><mixed-citation>Garris C.S., Arlauckas S.P., Kohler R.H. et al. Successful Anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-y and IL-12. Immunity 2018; 49(6): 1148-61.</mixed-citation></ref><ref id="B168"><label>168.</label><mixed-citation>Blackburn S.D., Shin H., Haining W.N. et al. Coregulation of CD8þ T cell exhaustion by multiple inhibitory receptors during chronic viral infec- tion. Nat. Immunol. 2009; 10: 29-37</mixed-citation></ref><ref id="B169"><label>169.</label><mixed-citation>Fourcade J., Sun Z., Benallaoua M. et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigenspecific CD8þ T cell dysfunction in melanoma patients. J. Exp. Med. 2010; 207(10): 2175-86.</mixed-citation></ref><ref id="B170"><label>170.</label><mixed-citation>170.Woo S.R., Turnis M.E., Goldberg M.V. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012; 72(4): 917-27.</mixed-citation></ref><ref id="B171"><label>171.</label><mixed-citation>Johnston R.J., Comps-Agrar L., Hackney J. et al. The immunore-ceptor TIGIT regulates antitumor and antiviral CD8(þ) T cell effector function. Cancer Cell 2014; 26(6): 923-37.</mixed-citation></ref><ref id="B172"><label>172.</label><mixed-citation>Chauvin J.M., Pagliano O., Fourcade J., et al. TIGIT and PD-1 impair tumor antigen-specific CD8(þ) T cells in melanoma patients. J. Clin. Invest. 2015; 125(5): 2046-58.</mixed-citation></ref><ref id="B173"><label>173.</label><mixed-citation>Damo M., Joshi N.S. Treg cell IL-10 and IL-35 exhaust CD8+ T cells in tumors. Nat. Immunol. 2019; 20(6): 674-5.</mixed-citation></ref><ref id="B174"><label>174.</label><mixed-citation>Aluvihare V.R., Kallikourdis M., Betz A.G. Regulatory T cells mediate maternal tolerance to the fetus. Nat. Immunol. 2004; 5(3): 266-71.</mixed-citation></ref><ref id="B175"><label>175.</label><mixed-citation>Robertson S.A., Care A.S., Moldenhauer L.M. Regulatory T cells in embryo implantation and the immune response to pregnancy. J. Clin. Invest. 2018; 128(10): 4224-35.</mixed-citation></ref><ref id="B176"><label>176.</label><mixed-citation>Du M.R., Guo P.F., Piao H.L. et al. Embryonic trophoblasts induce decidual regulatory T cell differentiation and maternal-fetal tolerance through thymic stromal lymphopoietin instructing dendritic cells. J. Immunol. 2014; 192(4): 1502-11.</mixed-citation></ref><ref id="B177"><label>177.</label><mixed-citation>Schumacher A., Zenclussen A.C. The Paternal Contribution to Fetal Tolerance. Adv. Exp. Med. Biol. 2015; 868: 211-25.</mixed-citation></ref><ref id="B178"><label>178.</label><mixed-citation>Ohue Y., Nishikawa H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? Cancer Sci. 2019; 110(7): 2080-9.</mixed-citation></ref><ref id="B179"><label>179.</label><mixed-citation>Schiaffino S., Pereira M.G., Ciciliot S. et al. Regulatory T cells and skeletal muscle regeneration. FEBS J. 2017; 284(4): 517-24.</mixed-citation></ref><ref id="B180"><label>180.</label><mixed-citation>Mathur A.N., Zirak B., Boothby I.C. et al. Treg-cell control of a CXCL5-IL-17 inflammatory axis promotes hair-follicle-stem-cell differentiation during skin-barrier repair. Immunity. 2019; 50(3): 655-67.</mixed-citation></ref><ref id="B181"><label>181.</label><mixed-citation>Ali N., Rosenblum M.D. Regulatory T cells in skin. Immunology 2017; 152(3): 372-81.</mixed-citation></ref><ref id="B182"><label>182.</label><mixed-citation>Li J., Tan J., Martino M.M. et al. Regulatory T-Cells: potential regulator of tissue repair and regeneration. Front. Immunol. 2018; 9: 585-96.</mixed-citation></ref><ref id="B183"><label>183.</label><mixed-citation>Morikawa M., Derynck R., Miyazono K. TGF-p and the TGF-p family: context-dependent roles in cell and tissue physiology. Cold Spring Harb. Perspect. Biol. 2016; 8(5): a021873. doi:10.1101/cshperspect.a021873.</mixed-citation></ref><ref id="B184"><label>184.</label><mixed-citation>Meng J., Liu Y., Guan S. et al. The establishment of immune infiltration based novel recurrence predicting nomogram in prostate cancer. Cancer Med. 2019; 8(11): 5202-13.</mixed-citation></ref><ref id="B185"><label>185.</label><mixed-citation>Moreno Ayala M.A., Li Z., DuPage M. Treg programming and therapeutic reprogramming in cancer. Immunology 2019; 157(3): 198-209.</mixed-citation></ref><ref id="B186"><label>186.</label><mixed-citation>Gianchecchi E., Fierabracci A. Inhibitory receptors and pathways of lymphocytes: the role of PD-1 in Treg development and their involvement in autoimmunity onset and cancer progression. Front. Immunol. 2018; 9: 2374-86.</mixed-citation></ref><ref id="B187"><label>187.</label><mixed-citation>Tosolini M., Kirilovsky A., Mlecnik B. et al. Clinical impact of different classes of infiltrating T. cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011; 71(4): 1263-71.</mixed-citation></ref><ref id="B188"><label>188.</label><mixed-citation>Тишевская Н.В., Бабаева А.Г., Геворкян Н.М. Роль лимфоцитарных РНК в межклеточном информационном обмене и регуляции регенеративных процессов. Российский физиологический журнал им. И.М. Сеченова. 2016; 102(11): 1280-1301.</mixed-citation></ref><ref id="B189"><label>189.</label><mixed-citation>Ekiz H.A., Ramstead A.G., Lee S.H. et al. T. cell-expressed microRNA-155 reduces lifespan in a mouse model of age-related chronic inflammation. J. Immunol. 2020; 204(8): 2064-75.</mixed-citation></ref><ref id="B190"><label>190.</label><mixed-citation>Ali S.A., Abdulrahman Z.F.A., Faraidun H.N. Circulatory miRNA- 155, miRNA-21 target PTEN expression and activity as a factor in breast cancer development. Cell. Mol. Biol. (Noisy-legrand). 2020; 66(7): 44-50.</mixed-citation></ref><ref id="B191"><label>191.</label><mixed-citation>Brahmer J.R., Tykodi S.S., Chow L.Q. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012; 366(26): 2455-65.</mixed-citation></ref><ref id="B192"><label>192.</label><mixed-citation>Li B., Chan H.L., Chen P. Immune checkpoint inhibitors: basics and challenges. Curr. Med. Chem. 2019; 26(17): 3009-25.</mixed-citation></ref><ref id="B193"><label>193.</label><mixed-citation>Сахин В.Т., Григорьев М.А., Е.В. Крюков и др. Патогенетические особенности развития анемии хронических заболеваний у больных со злокачественными новообразованиями и ревматической патологией. Онкогематология 2020; 15(4): 82-90.</mixed-citation></ref><ref id="B194"><label>194.</label><mixed-citation>Champiat S., Dercle L., Ammari S. et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/ PD-L1. Clin. Cancer Res. 2017; 23(8): 1920-8.</mixed-citation></ref><ref id="B195"><label>195.</label><mixed-citation>Yao H., Wang H., Li C. et al. Cancer cell-intrinsic PD-1 and implications in combinatorial immunotherapy. Front. Immunol. 2018; 9: 1774-81.</mixed-citation></ref><ref id="B196"><label>196.</label><mixed-citation>Kamada T., Togashi Y., Tay C. et al. PD-1 + regulatory T. cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc. Natl. Acad. Sci. USA. 2019; 116(20): 9999-10008.</mixed-citation></ref></ref-list></back></article>
